KD PHARMA

Serial Number 97376275
Registration 7593034
700

Registration Progress

Application Filed
Apr 22, 2022
Under Examination
Approved for Publication
Oct 8, 2024
Published for Opposition
Oct 8, 2024
Registered
Dec 10, 2024

Basic Information

Serial Number
97376275
Registration Number
7593034
Filing Date
April 22, 2022
Registration Date
December 10, 2024
Published for Opposition
October 8, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 10, 2024
Registration
Registered
Classes
001 005 029

Rights Holder

K.D. Pharma Bexbach GmbH

16
Address
Am Kraftwerk 6
Bexbach 66450
DE

Ownership History

K.D. Pharma Bexbach GmbH

Original Applicant
16
Bexbach DE

K.D. Pharma Bexbach GmbH

Owner at Publication
16
Bexbach DE

K.D. Pharma Bexbach GmbH

Original Registrant
16
Bexbach DE

Legal Representation

Attorney
KLAUS P. STOFFEL

USPTO Deadlines

Next Deadline
1980 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-12-10)
Due Date
December 10, 2030
Grace Period Ends
June 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description
Dec 10, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 10, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Oct 8, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 8, 2024 PUBO A PUBLISHED FOR OPPOSITION
Sep 18, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 4, 2024 EXPT T EXPARTE APPEAL TERMINATED
Sep 4, 2024 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY
Sep 4, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 4, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED
Sep 4, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 4, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED
Sep 4, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 1, 2024 GNS1 O NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Jul 1, 2024 GNSF O SUBSEQUENT FINAL EMAILED
Jul 1, 2024 CFRC R SUBSEQUENT FINAL REFUSAL WRITTEN
Jun 4, 2024 JURT T JURISDICTION RESTORED TO EXAMINING ATTORNEY
Jun 4, 2024 EXPI T EX PARTE APPEAL-INSTITUTED
Jun 4, 2024 EXAF T EXPARTE APPEAL RECEIVED AT TTAB
Jun 4, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 4, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Mar 4, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Dec 4, 2023 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED
Dec 4, 2023 GNFR O FINAL REFUSAL E-MAILED
Dec 4, 2023 CNFR R FINAL REFUSAL WRITTEN
Sep 21, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 20, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 20, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 19, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 19, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Mar 20, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 20, 2023 GNRT F NON-FINAL ACTION E-MAILED
Mar 20, 2023 CNRT R NON-FINAL ACTION WRITTEN
Mar 1, 2023 DOCK D ASSIGNED TO EXAMINER
Feb 18, 2023 DOCK D ASSIGNED TO EXAMINER
Feb 9, 2023 DOCK D ASSIGNED TO EXAMINER
Apr 27, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 26, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 001
Oils and fats, namely, lipids used in the manufacture of cosmetics, beverages, food products, pharmaceuticals and dietary supplements for the manufacture of pharmaceuticals, medical and veterinary preparations, sanitary preparations for medical purposes, dietetic foodstuffs and products for medical or veterinary purposes, food supplements for humans and animals, medicines and natural remedies, dietetic preparations and food supplements and pharmaceutical preparations and substances, dietary supplements and dietetic preparations, food for babies and infants, and for manufacturing beverages for infants and infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
Class 005
Pharmaceutical, medical and veterinary preparations, namely, pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines, and chemical reagents for medical or veterinary purposes, chemical reagents for medical or veterinary purposes; sanitary preparations for medical purposes; dietetic foodstuffs and goods for medical or veterinary purposes, namely, dietetic foods and beverages adapted for medical use, dietetic foods adapted for veterinary use, dietetic beverages adapted for veterinary use, and dietetic preparations adapted for medical purposes; food supplements for humans and animals; disinfectants; medicines and natural remedies, namely medicinal oils and antiallergic medicines, medicinal preparations for the treatment of infectious diseases and for use in oncology, medicinal drinks, medicinal preparations for infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, for the prevention and treatment of cancer, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria- based diseases, for the treatment of epilepsy, pain, anxiety, depression, sleep disorders, Parkinson's disease, nausea and vomiting, food disorders, arthritis, PTSD, schizophrenia, opioid addiction, alleviate ALS symptoms, multiple sclerosis, and for the treatment of diabetes, natural remedy preparations for the treatment of gastro-intestinal conditions, hormonal and chemical imbalances, and sleep disorders; dietetic preparations, namely Dietetic preparations adapted for medical purposes; food supplements; food for babies; food for infants; infant formula; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)
Class 029
Oils and fats, namely edible oils and edible fats and oils and fats for food; dietetic oils and fats in the nature of edible oils and fats, not for medical purposes; any cannabis or cannabis derived ingredients in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing containing cannabidiol (CBD)

Classification

International Classes
001 005 029

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"